NGeneBio Partners with MGI to Expand Cancer Testing Products Globally

MGI, a China-based company dedicated to developing core tools and technology to advance life science, and NGeneBio, a South Korean startup specialising in next-generation sequencing-based diagnostics, have signed a Memorandum of Understanding (MoU) to expand commercial access to NGeneBio's cancer testing products globally.

This strategic collaboration will allow for the integration of NGeneBio's advanced diagnostic assays with MGI's high-throughput sequencing technology, accelerating the development and application of cutting-edge sequencing products in the field of precision medicine and improving patient access to precise diagnostics and personalised treatment options.

Under the terms of the agreement, NGeneBio's NGS cancer precision diagnosis products will be integrated into MGI's sequencing platform DNBSEQ-G99, giving healthcare professionals access to a powerful and dependable tool for precision diagnosis and personalised treatment.

In addition, the two parties will also join forces in various regional clinical trials and collaborations across the Asia Pacific (APAC) region to strengthen the accessibility and commercialisation of cost-effective and state-of-the-art NGS solutions through MGI's extensive network of partners and distributors.